Japan’s biggest drug maker wants to cut jobs in its domestic market due to a shrinking market and falling drug prices. The downsizing plan comes after Takeda Pharmaceutical bought Shire PLC, a UK firm, for $59 billion. The company said it is considering voluntary early-retirement instead of forced redundancies. Takeda had announced a pause in new drug trials since March, except for its plasma-derived COVID-19 therapy.
Subscribe to our channel here: https://cna.asia/youtubesub
Subscribe to our news service on Telegram: https://cna.asia/telegram
Follow us:
CNA: https://cna.asia
CNA Lifestyle: http://www.cnalifestyle.com
Facebook: https://www.facebook.com/channelnewsasia
Instagram: https://www.instagram.com/channelnewsasia
Twitter: https://www.twitter.com/channelnewsasia